POET Technologies Announces Direct Offering of 20.7M Shares, Expected to Raise $150M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 22 2026
0mins
Source: Benzinga
- Funding Plan: POET Technologies has entered into securities purchase agreements with institutional investors to sell 20,689,656 common shares, expected to raise approximately $150 million, which will be utilized for corporate development and targeted acquisitions to enhance R&D capabilities.
- Market Reaction: Despite the Nasdaq gaining 1.01%, POET's stock fell 7.77% to $7.72, indicating a negative market response to the offering news, which may impact short-term investor confidence.
- Technical Indicators: The stock is currently trading 4.2% above its 20-day simple moving average and 22% above its 100-day moving average, indicating a strong long-term trend, with shares up 53.58% over the past 12 months, approaching 52-week highs.
- Earnings Expectations: Investors are looking forward to the upcoming earnings report, with an EPS estimate of a loss of 6 cents (an improvement from a loss of 48 cents YoY) and a revenue estimate of $0.62 million (up from $0.03 million YoY), indicating potential for earnings improvement.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like POET with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on POET
About POET
POET Technologies Inc. is a design and development company. It offers high-speed optical engines, light source products and custom optical modules to the artificial intelligence (AI) systems market and to hyperscale data centers. Its photonic integration solutions are based on the POET Optical Interposer, a novel, patented platform that allows the integration of electronic and photonic devices into a single chip using wafer-level semiconductor manufacturing techniques. Its Optical Interposer-based products consume less power than comparable products, are smaller in size and are readily scalable to high production volumes. In addition, it has designed and produced novel light source products for chip-to-chip data communication within and between AI servers, the next frontier for solving bandwidth and latency problems in AI systems. Its Optical Interposer platform solves device integration challenges across a range of communication, computing and sensing applications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Poet Technologies Issues 20.7 Million Shares to Raise $150 Million, Stock Plummets 17%
- Capital Raising Announcement: Poet Technologies revealed plans to issue 20.7 million shares, aiming to raise approximately $150 million, which led to a 17% drop in stock price, indicating strong market discontent with the financing effort.
- Significant Stock Impact: The share price is set at about $7.25, resulting in a market cap reduction to approximately $759 million, reflecting investor concerns over dilution of existing shares.
- Clear Use of Proceeds: The company intends to allocate the raised funds to enhance research and development as well as the development of high-speed optical modules and light sources, particularly for applications in artificial intelligence infrastructure, demonstrating its focus on future market opportunities.
- Market Reaction Analysis: Although the financing may dilute shares, analysts believe that investing in AI technology holds substantial potential, possibly presenting a buying opportunity for long-term investors in Poet as the sector continues to grow.
Continue Reading
Abbott Laboratories (ABT) Reports Q4 Sales Below Expectations, Stock Drops 7%
- Sales Performance Miss: Abbott Laboratories reported Q4 2025 sales of $11.46 billion, slightly below the consensus estimate of $11.80 billion, with a 4.4% increase in sales but only 3% organic growth, indicating competitive pressure in the market.
- Earnings Outlook Disappointment: Although adjusted earnings per share of $1.50 met Wall Street expectations, the overall performance failed to boost investor confidence, resulting in a stock drop of over 7% on Thursday, reflecting concerns about future growth.
- Market Reaction Intense: Following Abbott's earnings report, the significant stock decline illustrates investor pessimism regarding the company's future performance, which may impact its market position in the MedTech sector.
- Industry Impact Significant: Abbott's disappointing results could trigger a ripple effect across the MedTech industry, prompting investors to reassess the financial health of other related companies, potentially leading to overall valuation fluctuations in the sector.
Continue Reading